Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Luxdegalutamide · JSB462, ARV-766

Small molecule (PROTAC degrader) · Degrader of Androgen receptor (AR) · developed by Novartis Pharmaceuticals

Phase 2 Most advanced trial
NVS Developer
1 Registered trials

What is Luxdegalutamide?

Luxdegalutamide is an orally bioavailable PROTAC protein degrader that links an androgen receptor ligand to an E3 ligase recruiter. It binds the androgen receptor ligand-binding domain, recruits E3 ligase to tag the receptor with ubiquitin, and promotes its proteasomal degradation. It is being studied in castration-resistant prostate cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
JSB462, ARV-766
Drug type
Small molecule (PROTAC degrader)
Targets
Androgen receptor (AR)
Mechanism
Degrader of Androgen receptor (AR)
Pathways
AR-mediated signaling, ubiquitin-proteasome degradation
Therapy area
Oncology
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
5BD7R933PV

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06991556 Phase 2 Metastatic Hormone-sensitive Prostate Cancer Active not recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Prostatic Cancer, Castration-Resistant

Other drugs acting on AR

More from Novartis Pharmaceuticals

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Luxdegalutamide

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.